ACTIVITY IN THE THIRD QUARTER OF 2012
ACTIVITY IN THE THIRD QUARTER OF 2012
(Unaudited data)
- CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2012
| thousands of euros | 2011 | 2012 | Variation at current exchange rates | Variation at constant exchange rates |
| France | 210,153 | 233,426 | +11.1% | +11.1% |
| International : | 163,491 | 165,959 | +1.5% | +0.0% |
| Incl. Europe excluding France | 130,917 | 126,041 | -3.7% | -3.8% |
| Incl. North America | 26,756 | 31,282 | +16.9% | +7.5% |
| Incl. Other countries | 5,818 | 8,636 | +48.4% | +50.3% |
| Group Total | 373,644 | 399,385 | +6.9% | +6.2% |
| thousands of euros | 2011 | 2012 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 195,031 | 213,592 | +9.5% | +9.1% |
| OTC Specialties | 178,561 | 185,394 | +3.8% | +2.9% |
| Other | 0,052 | 0,399 | ||
| Group Total | 373,644 | 399,385 | +6.9% | +6.2% |
- DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER (VARIATION AT CURRENT RATE)
| thousands of euros | 1st Quarter | 2nd Quarter | 3rd Quarter | ||||||
| 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. | |
| France | 70,466 | 74,188 | +5.3% | 59,744 | 71,210 | +19.2% | 79,943 | 88,028 | +10.1% |
| International : | 58,478 | 54,904 | -6.1% | 37,128 | 41,216 | +11.0% | 67,885 | 69,839 | +2.9% |
| Incl. Europe excluding France | 47,024 | 41,807 | -11.1% | 28,880 | 28,889 | +0.0% | 55,013 | 55,345 | +0.6% |
| Incl. North America | 9,566 | 10,285 | +7.5% | 6,113 | 9,861 | +61.3% | 11,077 | 11,136 | +0.5% |
| Incl. Other countries | 1,888 | 2,812 | +48.9% | 2,135 | 2,466 | +15.5% | 1,795 | 3,358 | +87.1% |
| Group Total | 128,944 | 129,092 | +0.1% | 96,872 | 112,426 | +16.1% | 147,828 | 157,867 | +6.8% |
| thousands of euros | 1st Quarter | 2nd Quarter | 3rd Quarter | ||||||
| 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. | |
| Non-proprietary Homeopathic Medicines | 69,371 | 73,427 | +5.8% | 62,414 | 70,206 | +12.5% | 63,246 | 69,959 | +10.6% |
| OTC Specialties | 59,417 | 55,576 | -6.5% | 34,499 | 42,007 | +21.8% | 84,645 | 87,811 | +3.7% |
| Other | 0,156 | 0,089 | -0,041 | 0,213 | -0,063 | 0,097 | |||
| Group Total | 128,944 | 129,092 | +0.1% | 96,872 | 112,426 | +16.1% | 147,828 | 157,867 | +6.8% |
- THIRD QUARTER HIGHLIGHTS
- Sales revenue in the third quarter grew by 6.8% at actual exchange rates (5.9% at constant exchange rates):
- In France, sales of non-proprietary medicines increased by 15.3% due to the price increases applied to some of them.
- Internationally, the trends varied between countries. Sales increased by 2.9% notably due to favorable currency impacts.
- As of September 30, 2012, the group's net cash amounted to €98.7 million (versus €76.2 million as of June 30, 2012). This improvement in the group's net cash position was related to the growth in sales as well as decreases in investment expenditures.
- In the United States, the settlement agreement signed on March 6, 2012 aiming at putting an end to all class action litigation in process (with the exception of the lawsuit related to Children's Coldcalm®) has obtained the prior approval of the San Diego court. A hearing on the agreement final approval took place on October 1, 2012. Boiron USA is awaiting the court's decision.
-
OUTLOOK
Despite uncertainties related to the economic environment, Boiron confirms its targets of increased sales revenue and income in 2012.
-
CENTRAL WORKS COUNCIL MEETING
On October 25, 2012, the central works council of BOIRON SA met within the framework of an information and consultation procedure. Senior management reminds the council of the provisions of the European Directive on the status of homeopathic medicines in France and the consequences that could arise in the medium term for the company's strategy and organization. Senior management indicated that it currently foresees no immediate social consequences.
Next update: January 24th 2013, after the close of the stock market, publication of 2012 sales.
Financial information manager: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 4.78.45.63.43 - e-mail: [email protected]
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at : www.boiron.com
Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-29791-cp-boiron-251012.pdf
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-29791-cp-boiron-251012.pdf
<!-- 90 -->
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Boiron S.A. Stock
€32.10
-1.530%
